CN101426764A - 具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物 - Google Patents

具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物 Download PDF

Info

Publication number
CN101426764A
CN101426764A CNA2007800140984A CN200780014098A CN101426764A CN 101426764 A CN101426764 A CN 101426764A CN A2007800140984 A CNA2007800140984 A CN A2007800140984A CN 200780014098 A CN200780014098 A CN 200780014098A CN 101426764 A CN101426764 A CN 101426764A
Authority
CN
China
Prior art keywords
compound
formula
ethyl
methyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800140984A
Other languages
English (en)
Chinese (zh)
Inventor
皮埃尔-让·科尔松
阿达姆·休斯
克雷格·胡斯费尔德
马塔伊·马梅恩
米罗斯拉夫·拉普塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiwan Pharmaceutical
Original Assignee
Shiwan Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiwan Pharmaceutical filed Critical Shiwan Pharmaceutical
Publication of CN101426764A publication Critical patent/CN101426764A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA2007800140984A 2006-04-25 2007-04-24 具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物 Pending CN101426764A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79470206P 2006-04-25 2006-04-25
US60/794,702 2006-04-25

Publications (1)

Publication Number Publication Date
CN101426764A true CN101426764A (zh) 2009-05-06

Family

ID=38577470

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800140984A Pending CN101426764A (zh) 2006-04-25 2007-04-24 具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物

Country Status (20)

Country Link
US (3) US7524965B2 (enExample)
EP (1) EP2010489B1 (enExample)
JP (1) JP2009541209A (enExample)
KR (1) KR20090005389A (enExample)
CN (1) CN101426764A (enExample)
AR (1) AR060647A1 (enExample)
AU (1) AU2007243481A1 (enExample)
BR (1) BRPI0710767A2 (enExample)
CA (1) CA2650530A1 (enExample)
CO (1) CO6140054A2 (enExample)
ES (1) ES2391584T3 (enExample)
IL (1) IL194334A0 (enExample)
MA (1) MA30556B1 (enExample)
MX (1) MX2008013555A (enExample)
NO (1) NO20084603L (enExample)
PE (1) PE20080094A1 (enExample)
RU (1) RU2008146383A (enExample)
TW (1) TW200811105A (enExample)
WO (1) WO2007127196A2 (enExample)
ZA (1) ZA200808817B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409556A (zh) * 2022-01-28 2022-04-29 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008510014A (ja) * 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TW200811105A (en) * 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
WO2009098448A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Compounds
DK2599778T3 (en) 2009-04-23 2017-06-26 Theravance Respiratory Co Llc Diamide compounds with muscarinic receptor antagonist and beta-2 adrenergic receptor agonist activity
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US20110020423A1 (en) 2009-07-22 2011-01-27 Puretech Ventures Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
AU2019346626B2 (en) 2018-09-28 2022-06-02 Karuna Therapeutics, Inc. Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
AU685225B2 (en) 1994-02-10 1998-01-15 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
PE20040950A1 (es) * 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
JP2007528416A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
US7569586B2 (en) 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
TWI374883B (en) 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200811104A (en) * 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114409556A (zh) * 2022-01-28 2022-04-29 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN114409556B (zh) * 2022-01-28 2024-10-18 兰州康鹏威耳化工有限公司 一种3,4-二取代-2-氨基苯甲醛的制备方法
CN117924216A (zh) * 2024-01-12 2024-04-26 王叔和生物医药(武汉)有限公司 一种1-哌啶丙酸的合成方法

Also Published As

Publication number Publication date
US7524965B2 (en) 2009-04-28
US20070249675A1 (en) 2007-10-25
TW200811105A (en) 2008-03-01
KR20090005389A (ko) 2009-01-13
AR060647A1 (es) 2008-07-02
MX2008013555A (es) 2008-11-04
US8134006B2 (en) 2012-03-13
CA2650530A1 (en) 2007-11-08
EP2010489B1 (en) 2012-08-22
RU2008146383A (ru) 2010-05-27
JP2009541209A (ja) 2009-11-26
WO2007127196A3 (en) 2007-12-21
WO2007127196A2 (en) 2007-11-08
US20090176833A1 (en) 2009-07-09
BRPI0710767A2 (pt) 2011-06-07
AU2007243481A1 (en) 2007-11-08
NO20084603L (no) 2008-11-19
CO6140054A2 (es) 2010-03-19
MA30556B1 (fr) 2009-07-01
IL194334A0 (en) 2009-08-03
PE20080094A1 (es) 2008-02-17
ES2391584T3 (es) 2012-11-28
US7687521B2 (en) 2010-03-30
EP2010489A2 (en) 2009-01-07
US20100137603A1 (en) 2010-06-03
ZA200808817B (en) 2010-03-31

Similar Documents

Publication Publication Date Title
CN101426764A (zh) 具有β2肾上腺素能受体激动剂和毒蕈碱受体拮抗剂活性的二烷基苯基化合物
CN101426765A (zh) 二甲基苯基化合物的晶形
CN1930125B (zh) 适用作毒蕈碱性受体拮抗剂的联苯基化合物
KR101224497B1 (ko) 베타2 아드레날린 수용체 작용제 및 무스카린 수용체 길항제 활성을 갖는 비페닐 유도체
TWI570115B (zh) 具蕈毒鹼受體拮抗劑及β腎上腺素受體激動劑活性之二醯胺化合物
CA2810896A1 (en) Crystalline oxalate salts of a diamide compound
EP1723111A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087734A1 (en) Biphenyl compounds useful as muscarinic receptor antagonists
CN101239970B (zh) 联苯衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090506